{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-010791","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2024-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.142170+00:00","generated_at":"2026-06-04T22:05:22.617280+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aadi Bioscience reports FY2023 revenue $24.4M (+60% YoY); net loss $65.8M","bullets":["FYARRO net sales $24.4M for FY2023, up 60% YoY; Q4 sales $6.3M (+21% YoY).","Net loss $65.8M for FY2023 vs $60.5M in 2022; cash $108.8M funding into Q4 2025.","PRECISION1 trial enrollment on track to complete by May 2024; two-thirds interim analysis expected Q3 2024.","Phase 2 trials in accelerated endometrial cancer (EEC) and neuroendocrine tumors (NETs) actively enrolling."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-010791","json":"https://secwatch.observer/filing/0001628280-24-010791.json","markdown":"https://secwatch.observer/filing/0001628280-24-010791.md","text":"https://secwatch.observer/filing/0001628280-24-010791.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000162828024010791/0001628280-24-010791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000162828024010791/aadi-20240313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:05:22.617280+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b9434afd899d2e222e21502643d58451eb88ab7e","claim":"Whitehawk Therapeutics, Inc. reported Full year ended December 31, 2023 results: revenue $24.4 million, net income -$65.8 million.","evidence_excerpt":"(EX-99.1) --- Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update FYARRO® sales of $6.3 million for Q4 2023 and $24.4 million for FY 2023 representing year-over-year growth of 21% and 60%, respectively Registration-directed PRECISION1 trial of nab-sirolimus in solid tumors with TSC1 or TSC2 inactivating","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000162828024010791/0001628280-24-010791-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full year ended December 31, 2023"},{"label":"Revenue","value":"$24.4 million"},{"label":"Net income","value":"-$65.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e25860b617631be929c6c83f406499692d960407","claim":"Whitehawk Therapeutics, Inc. reported Three months ended December 31, 2023 results: revenue $6.3 million, net income -$16.3 million.","evidence_excerpt":"Total revenue for the quarter ended December 31, 2023, was $6.3 million, and $24.4 million for the full-year ended December 31, 2023, resulting from sales of FYARRO.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000162828024010791/0001628280-24-010791-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Three months ended December 31, 2023"},{"label":"Revenue","value":"$6.3 million"},{"label":"Net income","value":"-$16.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}